 HAMPTON, N.J., June 04, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today announced preliminary data from the Companys Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a poster session as part of the American Society of Clinical Oncology ASCO 2021 Annual Meeting taking place June 4-8, 2021. 